NASDAQ:APRI - Apricus Biosciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.40 -0.01 (-2.44 %) (As of 07/22/2018 04:00 PM ET)Previous Close$0.40Today's Range$0.39 - $0.427052-Week Range$0.25 - $3.34Volume289,307 shsAverage Volume368,924 shsMarket Capitalization$9.38 millionP/E Ratio-0.40Dividend YieldN/ABeta1.3 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California. Receive APRI News and Ratings via Email Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:APRI CUSIPN/A Webwww.apricusbio.com Phone858-222-8041 Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio3.50 Price-To-Earnings Trailing P/E Ratio-0.40 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.76 million Price / Sales1.63 Cash FlowN/A Price / CashN/A Book Value$0.29 per share Price / Book1.38 Profitability EPS (Most Recent Fiscal Year)($0.99) Net Income$320,000.00 Net MarginsN/A Return on Equity-193.26% Return on Assets-137.09% Miscellaneous Employees11 Outstanding Shares23,440,000Market Cap$9.38 Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions What is Apricus Biosciences' stock symbol? Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI." How were Apricus Biosciences' earnings last quarter? Apricus Biosciences Inc (NASDAQ:APRI) issued its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. View Apricus Biosciences' Earnings History. What price target have analysts set for APRI? 1 equities research analysts have issued 12 month target prices for Apricus Biosciences' stock. Their predictions range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Ratings for Apricus Biosciences. What is the consensus analysts' recommendation for Apricus Biosciences? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apricus Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Apricus Biosciences' key competitors? Some companies that are related to Apricus Biosciences include Onconova Therapeutics (ONTX), Nemus Bioscience (NMUS), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), PLx Pharma (PLXP), KITOV PHARMA LT/S (KTOV), SUMMIT THERAPEU/S (SMMT), Ceapro (CRPOF), NeuroVive Pharmaceutical (NEVPF), OvaScience (OVAS), Q BioMed (QBIO), Xenetic Biosciences (XBIO), Vistagen Therapeutics (VTGN), AEterna Zentaris (AEZS) and Edge Therapeutics (EDGE). Who are Apricus Biosciences' key executives? Apricus Biosciences' management team includes the folowing people: Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 54)Mr. Brian T. Dorsey, Sr. VP & Chief Devel. Officer (Age 49)Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 42)Ms. Kelly Deck, Exec. Director of Fin.Ms. Mary Naggs, VP & Gen. Counsel Has Apricus Biosciences been receiving favorable news coverage? Media coverage about APRI stock has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apricus Biosciences earned a coverage optimism score of 0.20 on Accern's scale. They also gave press coverage about the company an impact score of 46.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. How do I buy shares of Apricus Biosciences? Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Apricus Biosciences' stock price today? One share of APRI stock can currently be purchased for approximately $0.40. How big of a company is Apricus Biosciences? Apricus Biosciences has a market capitalization of $9.38 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe. How can I contact Apricus Biosciences? Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected] MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 142 (Vote Outperform)Underperform Votes: 120 (Vote Underperform)Total Votes: 262MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?